ASCO 2022 Conference Coverage


 

ASCO 2022 Efficacy & Safety Results From the Phase 3 ASCEMBL Study of Asciminib vs. Bosutinib in CP-CML After ≥2 Prior TKIs: Week 96 Update

269 views
July 12, 2022
Comments 0
Login to view comments. Click here to Login